Document:

EX-10.8

 Exhibit 10.8 

CONSENT TO ASSIGNMENT AGREEMENT 

BETWEEN 

CONNETICS AND 

INTERMUNE PHARMACEUTICALS, INC. 

JUNE 23, 2000 

THIS CONSENT TO ASSIGNMENT AGREEMENT (this
“Agreement”) is made effective and entered into as of June 23, 2000 (the “Effective Date”) by and between GENENTECH, INC., a Delaware corporation, with a principal place of business at 1
DNA Way, South San Francisco, California 94080 (“Genentech”), CONNETICS CORPORATION, a Delaware corporation, with a principal place of business at 3400 Bayshore Road, Palo Alto, California 94303
(“Connetics”) and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010
(“InterMune”). Genentech, Connetics and InterMune may be referred to herein as a “Party” or collectively as the “Parties.” 

RECITALS 

A. WHEREAS, InterMune is a corporation formed for the purpose of research and development of biopharmaceutical products
for the treatment of infectious and autoimmune diseases; 
 B. WHEREAS, Connetics has licensed the rights to certain
immunology-based products and to the technology relating thereto from Genentech pursuant to that certain License Agreement for Interferon Gamma by and between Connetics and Genentech, dated May 5, 1998, as amended (the “Genentech
License”); 
 C. WHEREAS, InterMune and Connetics have entered into that certain Amended and Restated Exclusive
Sublicense Agreement, dated April 27, 1999 (the “Original Agreement”), pursuant to which (a) Connetics granted an exclusive sublicense to InterMune under the Genentech License to develop, make, have made, import, offer for sale
and sell therapeutic products containing or derived from such immunology-based products and technology for use for certain specific indications, and (b) InterMune granted to Connetics the exclusive option to practice such sublicensed rights in
the dermatology field; 
 D. WHEREAS, InterMune and Connetics now desire to supersede and replace the Original
Agreement in order to assign to InterMune Connetics’ entire right, title and interest in, to and under the Genentech License by entering into that certain Assignment and Option Agreement, in the form attached hereto as Exhibit A (the
“Assignment Agreement”); and 
 E. WHEREAS, pursuant to section 12.4 of the Genentech License, with the prior
written consent of Genentech, Connetics may assign the Genentech License to InterMune. 
 NOW
THEREFORE, in consideration of the above recitals and the covenants set forth herein, the parties hereto agree as follows: 

 1. Genentech consents to the assignment by Connetics to InterMune of all Connetics’
right, title and interest in and to the Genentech License. 
 2. On the Effective Date, Genentech unconditionally releases and
discharges Connetics from any and all obligations under the Genentech License, and Genentech deems InterMune to be the successor in interest of Connetics under the Genentech License. Notwithstanding the above, Connetics shall remain responsible for
all of its obligations, if any, under Section 8.1 of the Genentech License. 
 3. InterMune shall assume all of the
obligations of and is entitled to all the rights of Connetics under the Genentech License, except that Connetics shall remain responsible for all of its obligations, if any, under Section 8.1 of the Genentech License. 

4. Section 1.28 of the Genentech License is hereby amended in its entirety to read as follows: 

“1.28 “Territory” shall mean the United States of America and Canada, and their respective territories and possessions, and
Japan.” 
 5. Nothing herein shall alter or affect the Stock Agreement or Stock Agreement Amendment (both defined in the
Genentech License) between Connetics and Genentech. 
 6. This agreement may be executed in two or more counterparts, each of
which shall be an original and all of which shall constitute together the same document. 
 7. This agreement shall be governed
in accordance with the laws of the State of California, exclusive of its conflicts of laws provisions. 
 IN
WITNESS WHEREOF, each of Genentech, Connetics and InterMune have executed this Agreement, as of the day and year first written above. 
  

									
	INTERMUNE PHARMACEUTICALS, INC.	 		 	GENENTECH, INC.
					
	By:	 	/s/ W. Scott Harkonen	 		 	By:	 	/s/ Art Levinson

									
	Print Name:	 	W. Scott Harkonen	 		 	Print Name:	 	Art Levinson

									
	Title:	 	Pres. & CEO	 		 	Title:	 	CEO

  

			
	CONNETICS CORPORATION
		
	By:	 	/s/ Thomas G. Wiggans

			
	Print Name:	 	Thomas G. Wiggans

			
	Title:	 	Pres. & CEO

  
 2EX-10.9

 Exhibit 10.9 

January 25, 2001 
 Ms. Anna Hall 

Director of Business Development 
 Genentech, Inc. 

1 DNA Way 
 South San Francisco 

CA 94080-4990 
  

	RE:	AMENDMENT NO. 5 TO THE INTERMUNE/GENENTECH LICENSE AGREEMENT

 Dear Ms. Hall: 
 Please consider this
document as Amendment No. 5 to that certain License Agreement for Interferon Gamma, dated May 5, 1998; as amended on December 26, 1998; January 15, 1999; April 27, 1999; and June 23, 2000 (collectively, the
“Agreement”), between INTERMUNE PHARMACEUTICALS, INC. and GENENTECH, INC. (collectively, the “Parties”). 

1. The Parties agree that the first sentence of Section 2.2(b) of the Agreement is hereby terminated in its entirety and amended and
superseded as follows: 
 “(b) Use of the Mark. In using the Actimmune mark, InterMune shall display said mark with either the first
letter in uppercase (i.e., Actimmune) or all letters in uppercase (i.e., ACTIMMUNE).” 
 2. All other sections and exhibits of the
Agreement remain unchanged. 
 3. This Amendment No. 5 to the Agreement is made effective as of January 25, 2001. 

IN WITNESS THEREOF, the parties have executed this Amendment No. 5 to the Agreement as of the date set forth below.

  

									
	INTERMUNE PHARMACEUTICALS, INC.	 		 	 GENENTECH, INC.

											
						
	By	 	/s/ John Wulf	 		 	By	 	/s/ Joseph S. McCracken	 	 

									
		 	John Wulf	 		 	      Print Name:	 	Joseph S. McCracken

									
		 	Sr. Vice President of Corporate Development	 		 	 Title:	 	VP Business Development

									
					
	Date	 	January 25, 2001	 		 	  Date:	 	4/5/01EX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY WITH
THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT No. 6 to the License Agreement for Interferon Gamma 

THIS AMENDMENT NUMBER SIX TO THE LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective February, 2006 (the
“Amendment Effective Date”), by and between Genentech, Inc. (“Genentech”) and InterMune, Inc. (“InterMune”). Genentech and InterMune may each be referred to herein as a “Party” and jointly as the
“Parties.” 
 RECITALS 

WHEREAS, Genentech and InterMune are each parties to that certain License Agreement for Interferon Gamma executed on May 5, 1998,
as amended to date (the “Agreement”); and 
 WHEREAS, Genentech and InterMune desire to further amend the Agreement
as specified herein below. 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions hereinafter set forth, and
intending to be legally bound, Genentech and InterMune hereby agree as follows: 
 Except as modified and/or amended herein, all of the terms,
covenants and conditions contained in the Agreement shall remain unchanged and in full force and effect. The term “Agreement”, as used in the Agreement, and all other instruments and agreements executed thereunder, shall for all purposes
refer to the Agreement as amended by this Amendment. This Amendment may be executed in counterpart, each of which shall be deemed to be an original, and such counterparts together shall constitute one instrument. In the event of a conflict among the
terms and conditions of this Amendment, and the Agreement, the following order of precedence shall prevail: 
 a. this Amendment; and

 b. the Agreement. 

CHANGES TO THE AGREEMENT. THE FOLLOWING CHANGES
ARE HEREBY MADE TO THE AGREEMENT: 

(a) Section 3.2. Section 3.2 is hereby deleted in its entirety and replaced with the following new Section 3.2:

 “3.2 Diligence. InterMune shall use its Best Efforts to develop and commercialize Licensed Products in the Field of
Use and in the Gene Therapy Field of Use, in accordance with the development plan roadmap set forth on Exhibit E hereto (the “Development Plan Roadmap”).” 

  
 1 

 (b) Section 3.3. Section 3.3 is hereby deleted in its entirety and replaced
with the following new Section 3.3: 
 “3.3 Review of Clinical Development Plan and Marketing Programs. On or
about each August 1 during the term of this Agreement, InterMune shall supply Genentech with a report on InterMune’s development and marketing programs for Licensed Products in the Field of Use and the Gene Therapy Field of Use in the
Territory. The report shall include the following: (i) a description of InterMune’s progress in such programs during the twelve (12) months prior to the date of each such report, and (ii) a description of InterMune’s planned
development and marketing programs for the twelve (12) months after the date of each such report. Genentech shall have the right to comment on the development and marketing programs, and at Genentech’s discretion, the Parties shall meet to
discuss and agree upon changes to such development and marketing programs.” 
 (c) Section 3.8. Section 3.8 is
hereby deleted in its entirety and replaced with the following new Section 3.8: 
 “3.8 Clinical Development
Reports. In connection with InterMune’s reporting obligations set forth in Section 3.3 hereof with respect to the development of Licensed Products and clinical studies conducted by InterMune hereunder, InterMune shall provide to Genentech
any information/report set forth in Exhibit F hereto as may be requested by Genentech in writing. InterMune shall submit such information/report to Genentech as promptly as reasonably practicable after such reports are completed or such applicable
information is available.” 
 (d) Exhibit E. Exhibit E is hereby deleted in its entirety and replaced with the new Exhibit E
attached hereto. 
 (e) In Witness Whereof, THE PARTIES HAVE CAUSED
THIS AMENDMENT TO BE EXECUTED BY THE RESPECTIVE DULY AUTHORIZED OFFICERS
AS OF THE DATE FIRST WRITTEN ABOVE. 
  

									
	GENENTECH, INC.	 		 	INTERMUNE, INC.
					
	By:	 	/s/ Joseph S. McCracken	 		 	By:	 	/s/ Tom Kassberg

									
	Printed Name: Joseph S. McCracken	 		 	Printed Name: Tom Kassberg
	Title: VP Business Development	 		 	Title: Sr. VP Corporate Development

  
 2 

 Exhibit E 

*** 
 ***. 

***
                                         
                                         
                                         
                                         
                                         
                                         
                                         
                                         
                                         
                           . 

***. 
 ***
                                         
                                         
                                         
                                         
                                         
                                         
                                         
                                 .
                                         
                               . 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]